Rilpivirine (TMC-278)

A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 that is used in the treatment of HIV INFECTIONS. It is also used in combination with other ANTI-HIV AGENTS, since ANTIVIRAL DRUG RESISTANCE emerges rapidly when it is used alone.

Also Known As:

Networked: 191 relevant articles (7 outcomes, 32 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Crauwels, Herta: 14 articles (12/2021 - 07/2011)
2.	Vanveggel, Simon: 14 articles (12/2021 - 01/2010)
3.	Margolis, David A: 9 articles (12/2021 - 07/2015)
4.	Smith, Kimberly Y: 8 articles (12/2021 - 10/2015)
5.	Orkin, Chloe: 8 articles (11/2021 - 03/2013)
6.	De Clercq, Erik: 8 articles (11/2016 - 01/2008)
7.	Boven, Katia: 8 articles (01/2014 - 01/2010)
8.	Ford, Susan L: 7 articles (11/2021 - 11/2013)
9.	Spreen, William R: 7 articles (11/2021 - 10/2015)
10.	Van Solingen-Ristea, Rodica: 6 articles (01/2022 - 01/2021)

Related Diseases

1.	Infections 01/01/2019 - "The population typical value of rilpivirine EC50 was estimated at 65 ng/mL. A higher infection rate constant of CD4 cells for HIV-1 was obtained in pre-treated patients. " 10/01/2017 - "Long-acting rilpivirine is a candidate for preexposure prophylaxis (PrEP) for prevention of HIV-1 infection. " 07/01/2015 - "This review summarizes these properties supporting the potential of intermittent parenteral administration of rilpivirine long acting (RPV LA) in both treatment and prevention of HIV-1 infection. " 06/01/2013 - "Position of rilpivirine in the management of infection by the human immunodeficiency virus]." 04/01/2018 - "Its availability in a long-acting injectable formulation (CAB-LA) makes it a valuable, novel drug to treat HIV-1 infection when combined with long-acting injectable rilpivirine (RPV-LA). "
2.	Acquired Immunodeficiency Syndrome (AIDS) 01/01/2018 - "International Maternal Pediatric Adolescent AIDS Clinical Trials Protocol P1026s is an ongoing, prospective study of antiretroviral pharmacokinetics in HIV-infected pregnant women that include a cohort receiving rilpivirine combination regimen. " 01/01/2016 - "International Maternal Pediatric Adolescent AIDS Clinical Trials P1026s is a multicenter, nonblinded, prospective study evaluating antiretroviral pharmacokinetics in HIV-infected pregnant women that included a cohort receiving rilpivirine 25 mg once daily as part of their combination antiretrovirals for clinical care. " 02/02/2023 - "Rilpivirine is an antiretroviral drug used to treat AIDS worldwide. " 12/01/2016 - "An unusual case of underlying rilpivirine resistance in an antiretroviral-naïve man with AIDS." 10/01/2016 - "Rilpivirine-containing ART was introduced in 162 HIV-1-infected patients at the outpatient clinic of the AIDS Clinical Center (National Center for Global Health and Medicine, Tokyo, Japan) between May 2012 and June 2015. "
3.	HIV Infections (HIV Infection) 07/01/2015 - "Pharmacokinetic data from Phase I studies suggest that 1200 mg of long-acting rilpivirine administered every 8 weeks would be associated with plasma and tissue levels of rilpivirine anticipated to be necessary for preventing HIV infection. " 04/01/2018 - "Rilpivirine, prescribed for the treatment of HIV infection, presents an important inter-individual pharmacokinetic variability. " 01/01/2018 - "Rilpivirine long-acting for the prevention and treatment of HIV infection." 08/01/2015 - "Together, our results demonstrate that topically- or systemically administered rilpivirine offers significant coitus-dependent or coitus-independent protection from HIV infection. " 09/16/2013 - "An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients."
4.	Viremia 11/16/2017 - "The proportion of time spent with residual viremia was comparable in the two groups (9% [IQR 0.5%-49%] and 17% [IQR 0.5%-50%] in the rilpivirine and in the InSTI group, p = 0.087). " 01/01/2015 - "In this clinical cohort of virologically-suppressed patients switching to a new STR, most subjects had adequate rilpivirine C24h and displayed a high level of virological suppression with no residual viremia until W96." 01/01/2023 - "Transient Viremia in Young Adults With HIV After the Switch to Long-Acting Cabotegravir and Rilpivirine: Considerations for Dosing Schedule and Monitoring." 01/01/2021 - "Phase 3 data support the efficacy of nanoformulated injectable cabotegravir and rilpivirine for HIV treatment in patients with undetectable viremia, but we have yet to learn how this strategy may benefit those with medication adherence challenges. " 10/12/2023 - "Predictors of virologic failure in those receiving long acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) have been evaluated, however factors associated with low-level viremia, including blips and persistent low-level viremia (pLLV) are not well described. "
5.	Deglutition Disorders (Dysphagia) 01/01/2017 - "Efficacy of switching to dolutegravir plus rilpivirine, the small-tablet regimen, in patients with dysphagia: two case reports."

Related Drugs and Biologics

1.	cabotegravir
2.	Reverse Transcriptase Inhibitors
3.	Nucleosides
4.	dolutegravir
5.	Tablets
6.	etravirine (TMC-125)
7.	efavirenz (Sustiva)
8.	Rilpivirine (TMC-278)
9.	Emtricitabine (Emtriva)
10.	Tenofovir (Viread)

Related Therapies and Procedures

1.	Injections
2.	Therapeutics
3.	Female Contraceptive Devices (Vaginal Ring)
4.	Art Therapy